Global Pulmonary / Respiratory Drug Delivery Market to Reach $77.7 Billion by 2030
The global market for Pulmonary / Respiratory Drug Delivery estimated at US$53.3 Billion in the year 2022, is projected to reach a revised size of US$77.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030. Metered Dose Inhalers, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$32.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dry Powder Inhalers segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $15.8 Billion, While China is Forecast to Grow at 4.5% CAGR
The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$15.8 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$13.6 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.Select Competitors (Total 42 Featured) -
- AireHealth, LLC
- Allergenix
- Channel Products
- Chemring Group PLC
- Epalex Corp.
- Genetic SpA
- Micot
- Omron Healthcare India
- Pneuma Respiratory
- Rotech Healthcare, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Pulmonary/ Respiratory Drug Delivery - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Pulmonary / Respiratory Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 11: World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Metered Dose Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Dry Powder Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Nebulizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- JAPAN
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- CHINA
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 44: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- EUROPE
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- FRANCE
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 59: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- GERMANY
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 95: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2023 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AireHealth, LLC
- Allergenix
- Channel Products
- Chemring Group PLC
- Epalex Corp.
- Genetic SpA
- Micot
- Omron Healthcare India
- Pneuma Respiratory
- Rotech Healthcare, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 53.3 Billion |
| Forecasted Market Value ( USD | $ 77.7 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
